Alpha 2.0
Login Register
» Articles » PMID: 34820232

Bilateral Thalamic Stroke: A Case of COVID-19 Vaccine-Induced Immune Thrombotic Thrombocytopenia (VITT) or a Coincidence Due to Underlying Risk Factors?

Overview
Journal Cureus
Specialty Biomedical Engineering
Date 2021 Nov 25
PMID 34820232
Citations 4
Authors
Richard Giovane
Jessica Campbell
Affiliations
Soon will be listed here.
Abstract

Vaccine-induced immune thrombotic thrombocytopenia (VITT) is a rare but potentially life-threatening side effect that has only been observed in adenovirus-based vaccines for coronavirus disease 2019 (COVID-19). VITT is an immune-mediated condition that generally presents within five to 10 days post-vaccination with thrombosis, thrombocytopenia, and coagulation abnormalities. A diagnosis of VITT is made clinically and through laboratory testing. Although VITT is an important differential to consider, it is believed that more emphasis should be placed on vaccination due to the safety and efficacy in overcoming COVID-19.

Citing Articles

Cerebellar and brainstem stroke possibly associated with booster dose of BNT162b2 (Pfizer-BioNTech) COVID-19 vaccine.

Thomas M, Dermawan A, Teh S BMJ Case Rep. 2023; 16(5).

PMID: 37147105 PMC: 10163425. DOI: 10.1136/bcr-2022-251180.

Acute ischemic stroke and vaccine-induced immune thrombotic thrombocytopenia post COVID-19 vaccination; a systematic review.

Kolahchi Z, Khanmirzaei M, Mowla A J Neurol Sci. 2022; 439:120327.

PMID: 35752132 PMC: 9212261. DOI: 10.1016/j.jns.2022.120327.

Headache onset after vaccination against SARS-CoV-2: a systematic literature review and meta-analysis.

Castaldo M, Waliszewska-Prosol M, Koutsokera M, Robotti M, Straburzynski M, Apostolakopoulou L J Headache Pain. 2022; 23(1):41.

PMID: 35361131 PMC: 8969402. DOI: 10.1186/s10194-022-01400-4.

COVID-19, Vaccines, and Thrombotic Events: A Narrative Review.

Abrignani M, Murrone A, De Luca L, Roncon L, Lenarda A, Valente S J Clin Med. 2022; 11(4).

PMID: 35207220 PMC: 8880092. DOI: 10.3390/jcm11040948.

References
1.
Frenck Jr R, Klein N, Kitchin N, Gurtman A, Absalon J, Lockhart S . Safety, Immunogenicity, and Efficacy of the BNT162b2 Covid-19 Vaccine in Adolescents. N Engl J Med. 2021; 385(3):239-250. PMC: 8174030. DOI: 10.1056/NEJMoa2107456. View
2.
Connors M, Graham B, Lane H, Fauci A . SARS-CoV-2 Vaccines: Much Accomplished, Much to Learn. Ann Intern Med. 2021; 174(5):687-690. PMC: 7839932. DOI: 10.7326/M21-0111. View
3.
Gee J, Marquez P, Su J, Calvert G, Liu R, Myers T . First Month of COVID-19 Vaccine Safety Monitoring - United States, December 14, 2020-January 13, 2021. MMWR Morb Mortal Wkly Rep. 2021; 70(8):283-288. PMC: 8344985. DOI: 10.15585/mmwr.mm7008e3. View
4.
Pavord S, Scully M, Hunt B, Lester W, Bagot C, Craven B . Clinical Features of Vaccine-Induced Immune Thrombocytopenia and Thrombosis. N Engl J Med. 2021; 385(18):1680-1689. PMC: 10662971. DOI: 10.1056/NEJMoa2109908. View
5.
Greinacher A, Selleng K, Palankar R, Wesche J, Handtke S, Wolff M . Insights in ChAdOx1 nCoV-19 vaccine-induced immune thrombotic thrombocytopenia. Blood. 2021; 138(22):2256-2268. PMC: 8483989. DOI: 10.1182/blood.2021013231. View